Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, BEONE MEDICINES LTD. reported revenue of $5.34B, up 40.2% year over year. Operating margin was 8.4% and net margin 5.4%, on a free-cash-flow margin of 17.6% with capital expenditure at 3.5% of revenue. Every figure is computed directly from ONC's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $5.34B | 8.4% | 5.4% |
| FY2024 | $3.81B | -14.9% | -16.9% |
| FY2023 | $2.46B | -49.1% | -35.9% |
| FY2022 | $1.42B | -126.4% | -141.5% |
| FY2021 | $1.18B | -122.3% | -123.9% |
How does ONC compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.